November 24, 2025 Dataset Open Access

Mayer, Leonie

Citation Style Language JSON Export

{"DOI":"10.25592/uhhfdm.17971","abstract":"<p><strong>Abstract</strong></p>\n\n<p>MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune responses remain detectable for at least 24 months after the third vaccination. &nbsp;Antibodies persisted at levels comparable to the peak response observed after the second vaccination and were able to cross-neutralize MERS-CoV spike mutants. Although the immune correlates of protection against MERS remain unknown, the observed durability of humoral and cellular immune responses supports the potential of MVA-MERS-S as a promising MERS vaccine candidate and highlights the importance of a booster dose in sustaining long-term immunity.</p>","author":[{"family":"Mayer, Leonie"}],"container_title":"Nature Communications","id":"17971","issued":{"date-parts":[[2025,11,24]]},"note":"This dataset includes the immunogenicity data of the manuscript.","title":"Two-year persistence of MERS-CoV-specific antibody and T cell responses  after MVA-MERS-S vaccination in healthy adults","type":"dataset"}